Literature DB >> 11311222

The evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behçet's disease.

K Köse1, C Yazici, O Aşşioğlu.   

Abstract

OBJECTIVE: Despite unknown etiology, immunologic alterations and neutrophil hyperfunctions may be involved in the etiopathogenesis of Behçet's Disease (BD). The purpose of the study was to investigate whether adenosine deaminase (ADA) activity, accepted as a nonspecific marker of T lymphocyte activation, may have a potential role in BD, and also may be related to the production of reactive oxygen species (ROS) by neutrophils. DESIGN AND METHODS: ADA activities and malondialdehyde (MDA; endproduct of lipid peroxidation induced by ROS) levels in both plasma and erythrocytes were spectrophotometrically measured in 25 patients with BD and also in 25 healthy controls.
RESULTS: ADA activity was found to be higher in plasma, but lower in erythrocytes; plasma and erythrocyte MDA levels were higher in BD patients than those of controls. In addition, plasma ADA activity was positively related to MDA levels in both plasma (p < 0.05) and erythrocytes (p < 0.01). There was also positive correlation between MDA levels (p < 0.05), but negative correlations between ADA activities (p < 0.01) and also between ADA and MDA values in erythrocytes (p < 0.01) of BD patients.
CONCLUSION: These findings may provide some evidence for a potential role of T lymphocyte activation in BD as reflected by increased plasma ADA activity, and for the presence of possible interrelationship between activated T cells and neutrophil hyperfunctions, such as ROS generation, as reflected by increased MDA levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311222     DOI: 10.1016/s0009-9120(01)00190-4

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  14 in total

1.  Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Authors:  Zeki Yesilova; Salih Pay; Cagatay Oktenli; Ugur Musabak; Kenan Saglam; S Yavuz Sanisoglu; Kemal Dagalp; M Kemal Erbil; Ismail H Kocar
Journal:  Rheumatol Int       Date:  2004-04-01       Impact factor: 2.631

2.  Oxidant/antioxidant status in men with Behçet's disease.

Authors:  Seyithan Taysi; Berna Demircan; Necmettin Akdeniz; Mustafa Atasoy; Refik Ali Sari
Journal:  Clin Rheumatol       Date:  2007-01-06       Impact factor: 2.980

3.  Therapeutic benefit of pentostatin in severe IL-10-/- colitis.

Authors:  Jeffrey B Brown; Goo Lee; Gery R Grimm; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

4.  Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease.

Authors:  Mustafa Calis; Filiz Ates; Cevat Yazici; Kader Kose; Mehmet Kirnap; Meltem Demir; Murat Borlu; Cem Evereklioglu
Journal:  Rheumatol Int       Date:  2005-05-03       Impact factor: 2.631

5.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

6.  N-acetyl cysteine suppresses the foam cell formation that is induced by oxidized low density lipoprotein via regulation of gene expression.

Authors:  Ho Joong Sung; Jeonghan Kim; Yoonseo Kim; Sung-Wuk Jang; Jesang Ko
Journal:  Mol Biol Rep       Date:  2011-06-17       Impact factor: 2.316

7.  Evaluation of nitric oxide synthase activity, nitric oxide, and homocysteine levels in patients with active Behcet's disease.

Authors:  Seyithan Taysi; Refik Ali Sari; Hakan Dursun; Adnan Yilmaz; Mustafa Keles; Kerim Cayir; Mehmet Akyuz; Abdullah Uyanik; Adem Guvenc
Journal:  Clin Rheumatol       Date:  2008-07-18       Impact factor: 2.980

8.  Serum prolidase enzyme activity and oxidative status in patients with Behçet's disease.

Authors:  Mehtap Bozkurt; Hatice Yüksel; Serda Em; Pelin Oktayoglu; Mehmet Yildiz; Dicle Akdeniz; Kemal Nas
Journal:  Redox Rep       Date:  2013-11-12       Impact factor: 4.412

9.  Effects of thyroid hormone analogue and a leukotrienes pathway-blocker on renal ischemia/reperfusion injury in mice.

Authors:  Najah R Hadi; Fadhil G Al-amran; Ayad A Hussein
Journal:  BMC Nephrol       Date:  2011-12-23       Impact factor: 2.388

10.  Sensitivity and specificity of adenosine deaminase in diagnosis of juvenile idiopathic arthritis.

Authors:  Mina Doudkani-Fard; Vahid Ziaee; Mohamad-Hassan Moradinejad; Mojtaba Sedaghat; Mohammad-Taghi Haghi-Ashtiani; Zahra Ahmadinejad
Journal:  Med J Islam Repub Iran       Date:  2014-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.